Kidney Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.
J Urol. 2011 Jan;185(1):60-6. doi: 10.1016/j.juro.2010.09.012. Epub 2010 Nov 12.
Vascular endothelial growth factor targeted therapy is a standard of care in patients with metastatic renal cell carcinoma. The role of cytoreductive nephrectomy in the era of novel agents remains poorly defined.
We retrospectively reviewed baseline characteristics and outcomes of 314 patients with anti-vascular endothelial growth factor therapy naïve, metastatic renal cell carcinoma from United States and Canadian cancer centers to study the impact of cytoreductive nephrectomy on overall survival.
Patients who underwent cytoreductive nephrectomy (201) were younger (p < 0.01), and more likely to have a better Karnofsky performance status (p < 0.01), more than 1 site of metastasis (p = 0.04) and lower corrected calcium levels (p < 0.01) compared to those who did not undergo cytoreductive nephrectomy (113). On univariable analysis cytoreductive nephrectomy was associated with a median overall survival of 19.8 months compared to 9.4 months for patients who did not undergo cytoreductive nephrectomy (HR 0.44; 95% CI 0.32, 0.59; p < 0.01). On multivariable analysis and adjusting for established prognostic risk factors the overall survival difference persisted (adjusted HR 0.68; 95% CI 0.46, 0.99; p = 0.04) in favor of the cytoreductive nephrectomy group. In subgroup analyses stratified for favorable/intermediate/poor risk criteria, patients in the poor risk group had a marginal benefit (p = 0.06). Similarly patients with Karnofsky performance status less than 80% also had a marginal survival benefit (p = 0.08).
In this retrospective study cytoreductive nephrectomy was independently associated with a prolonged overall survival of patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor targeted agents, although the benefit is marginal in those patients with poor risk features.
血管内皮生长因子靶向治疗是转移性肾细胞癌患者的标准治疗方法。在新型药物时代,细胞减灭性肾切除术的作用仍未得到明确界定。
我们回顾性分析了来自美国和加拿大癌症中心的 314 例抗血管内皮生长因子治疗初治、转移性肾细胞癌患者的基线特征和结局,以研究细胞减灭性肾切除术对总生存期的影响。
接受细胞减灭性肾切除术(201 例)的患者年龄较小(p < 0.01),卡氏功能状态评分较好(p < 0.01),转移部位多于 1 个(p = 0.04),校正钙水平较低(p < 0.01),而未接受细胞减灭性肾切除术(113 例)的患者则不然。单变量分析显示,与未接受细胞减灭性肾切除术的患者相比,接受细胞减灭性肾切除术的患者中位总生存期为 19.8 个月,而未接受细胞减灭性肾切除术的患者为 9.4 个月(HR 0.44;95%CI 0.32,0.59;p < 0.01)。多变量分析并调整了既定的预后危险因素后,这种总生存差异仍然存在(调整后的 HR 0.68;95%CI 0.46,0.99;p = 0.04),有利于细胞减灭性肾切除术组。根据有利/中等/差风险标准进行亚组分析时,在风险较差的患者中,患者有轻微获益(p = 0.06)。同样,卡氏功能状态评分低于 80%的患者也有轻微的生存获益(p = 0.08)。
在这项回顾性研究中,细胞减灭性肾切除术与接受血管内皮生长因子靶向药物治疗的转移性肾细胞癌患者的总生存期延长独立相关,尽管在风险较高的患者中获益较小。